Brady Kelly sold 64 shares of Seres Therapeutics, Inc. at $4.55 for −$291 on Aug 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
See Remarks
See Remarks
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$291.20Shares × reported price
Shares traded
64Common Stock
Price per share
$4.55Reported price. Read footnotes for ranges.
% of reported position traded
0.73%This security and ownership context
Holdings after
8,679Direct
Trade date
Aug 17, 2026Sell
Filed
Aug 18, 2026, 5:33 PM ET1-day reporting delay
Accession
0001193125-26-355734Code S · Transaction 3345
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 8,743 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 15, 2026Option exercise90$0.00$0Trade 3346
Aug 15, 2026Option exercise91$0.00$0Trade 3347
Aug 15, 2026Option exercise181——Trade 3344
4 transaction rows in this filing. Joint filers share the same rows.

MCRB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MCRB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +23%1w ago +15%1d ago +4.6%
Returns since7d +15%30d −5.8%90d180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.